What exactly did analysts change for Ultragenyx on March 12, 2026?

On March 12, 2026, Bank of America Securities **maintained Buy** for Ultragenyx (RARE) at 11:55 AM, and Leerink Partners **maintained Outperform** at 10:39 AM. Both notes reiterated positive views without issuing new price targets, per StreetInsider.

Did either analyst set a new RARE price target with their note?

No. The March 12, 2026 notes did not include new RARE price targets. The firms reiterated their positive stances and focused on pipeline strength and a clinical win rather than updating targets.

How should investors interpret the maintained RARE analyst rating?

A maintained RARE analyst rating signals continued analyst confidence but not fresh upside guidance. Investors should combine the notes with the company’s clinical calendar, cash position, and the **B+** Meyka AI grade when assessing risk and timing.

How did the stock react to the March 12, 2026 notes?

The notes coincided with modest intraday gains: **$0.28** or **1.31%** tied to the BofA note, and **$0.34** or **1.59%** tied to the Leerink note, indicating measured positive sentiment.

Analyst Ratings

Bank of America, Leerink Maintain Buy/Outperform on RARE Ultragenyx March 2026

ByDanny Kontos March 13, 2026March 13, 2026

Bank of America Securities and Leerink Partners both maintained positive views on Ultragenyx Pharmaceutical Inc. on March 12, 2026, keeping their Buy and Outperform ratings respectively. The RARE analyst rating update signals continued analyst confidence after recent clinical progress, and price moves of 1.31% and 1.59% accompanied the notes. Investors should read these maintained ratings as reaffirmations, not fresh upgrades or downgrades, and weigh them against the company’s market cap of $2,097,832,697 and pipeline milestones. Meyka AI provides this RARE analyst rating summary as part of our AI-powered market analysis platform.